Clearmind Medicine Inc. announced the filing of a European patent application for novel psychedelic compounds targeting PTSD treatment, strengthening its IP position under its exclusive licensing agreement with Yissum.
Key takeaways
Filed European patent application for innovative psychedelic compounds for PTSD and other mental health disorders.
Part of exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.
Clearmind holds exclusive global rights to develop, manufacture, and commercialize the novel compounds.
Company responsible for advancing development per regulatory requirements.
Strengthens IP portfolio in Europe, with current portfolio of nineteen patent families including 31 granted patents.